ArticleEuropean journal of clinical pharmacology2008
Disease progression, drug action and Parkinson's disease: why time cannot be ignored.
Article in European journal of clinical pharmacology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis.Journal of pharmacokinetics and pharmacodynamics · 2011Trial
- Sway frequencies may predict postural instability in Parkinson's disease: a novel convolutional neural network approach.Journal of neuroengineering and rehabilitation · 2025Article
- Prediction of Individual Disease Progression Including Parameter Uncertainty in Rare Neurodegenerative Diseases: The Example of Autosomal-Recessive Spastic Ataxia Charlevoix Saguenay (ARSACS).The AAPS journal · 2024Article
- Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.Journal of Parkinson's disease · 2024Article
- 'Anxious fluctuators' a subgroup of Parkinson's disease with high anxiety and problematic on-off fluctuations.Parkinsonism & related disorders · 2022Article
- Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease: Design and Evaluation of an Internet of Things System.JMIR formative research · 2022Article
- A Multi-Scale Computational Model of Levodopa-Induced Toxicity in Parkinson's Disease.Frontiers in neuroscience · 2022Article
- Baseline predictors of progression of Parkinson's disease in a sample of Egyptian patients: clinical and biochemical.The Egyptian journal of neurology, psychiatry and neurosurgery · 2022Article
- Impact of Off-Time on Quality of Life in Parkinson's Patients and Their Caregivers: Insights from Social Media.Parkinson's disease · 2022Article
- An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression.Journal of pharmacokinetics and pharmacodynamics · 2021Article
- Potential Markers of Progression in Idiopathic Parkinson's Disease Derived From Assessment of Circular Gait With a Single Body-Fixed-Sensor: A 5 Year Longitudinal Study.Frontiers in human neuroscience · 2019Article
- Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.British journal of clinical pharmacology · 2012Article
- Bone physiology, disease and treatment: towards disease system analysis in osteoporosis.Clinical pharmacokinetics · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.